Pharmacological management of gambling disorder: an update of the literature

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• World Health Organization. International statistical classification of diseases and related health problems (ICD-11). 11th ed. World Health Organization; 2019.
   Google Scholar
• Potenza MN, Balodis IM, Derevensky J, et al. Gambling disorder. Nat Rev Dis Prim. 2019;5(1). doi: 10.1038/s41572-019-0099-7
   PubMedGoogle Scholar
• Subramaniam M, Wang P, Soh P, et al. Prevalence and determinants of gambling disorder among older adults: a systematic review. Addict Behav. 2015;41:199–209. doi: 10.1016/j.addbeh.2014.10.007
   PubMed Web of Science ®Google Scholar
• Ioannidis K, Hook R, Wickham K, et al. Impulsivity in gambling disorder and problem gambling: a meta-analysis. Neuropsychopharmacol. 2019;44(8):1354–1361. doi: 10.1038/s41386-019-0393-9
   PubMed Web of Science ®Google Scholar
• Ghinassi S, Casale S. The role of attachment in gambling behaviors and gambling disorder: a systematic review. J Gambl Stud. 2022;39(2):713–749. doi: 10.1007/s10899-022-10163-1
   PubMed Web of Science ®Google Scholar
• Marchetti D, Verrocchio MC, Porcelli P. Gambling problems and alexithymia: a systematic review. Brain Sci. 2019;9(8):1–16. doi: 10.3390/brainsci9080191
   Web of Science ®Google Scholar
• Velotti P, Rogier G, Beomonte Zobel S, et al. Association between gambling disorder and emotion (dys)regulation: a systematic review and meta-analysis. Clin Psychol Rev. 2021;87:102037. doi: 10.1016/j.cpr.2021.102037
   PubMed Web of Science ®Google Scholar
• Mallorquí-Bagué N, Mestre-Bach G, Testa G. Craving in gambling disorder: a systematic review. J Behav Addict. 2023;12(1):53–79. doi: 10.1556/2006.2022.00080
   PubMed Web of Science ®Google Scholar
• Ribeiro EO, Afonso NH, Morgado P. Non-pharmacological treatment of gambling disorder: a systematic review of randomized controlled trials. BMC Psychiatry. 2021;21(1):105. doi: 10.1186/s12888-021-03097-2
   PubMed Web of Science ®Google Scholar
• Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914–921. doi: 10.1016/S0006-3223(01)01079-4
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69:783–789. doi: 10.4088/JCP.v69n0511
   PubMed Web of Science ®Google Scholar
• Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16(5):285–289. doi: 10.1097/00004850-200109000-00006
   PubMed Web of Science ®Google Scholar
• Ward S, Smith N, Bowden-Jones H. The use of naltrexone in pathological and problem gambling: a UK case series. J Behav Addict. 2018;7(3):827–833. doi: 10.1556/2006.7.2018.89
   PubMed Web of Science ®Google Scholar
• Kim SW, Grant JE, Yoon G, et al. Safety of high-dose naltrexone treatment. Clin Neuropharmacol. 2006;29(2):77–79. doi: 10.1097/00002826-200603000-00004
   PubMed Web of Science ®Google Scholar
• Kovanen L, Basnet S, Castrén S, et al. A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016;22(2):70–79. doi: 10.1159/000435876
   PubMed Web of Science ®Google Scholar
• Lahti T, Halme JT, Pankakoski M, et al. Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull. 2010;43:35–44.
   PubMedGoogle Scholar
• Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2):303–312. doi: 10.1176/appi.ajp.163.2.303
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Potenza MN, et al. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010;197(4):330–331. doi: 10.1192/bjp.bp.110.078105
   PubMed Web of Science ®Google Scholar
• Hollander E, DeCaria CM, Mari E, et al. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry. 1998;155(12):1781–1783. doi: 10.1176/ajp.155.12.1781
   PubMed Web of Science ®Google Scholar
• Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry. 2000;47(9):813–817. doi: 10.1016/S0006-3223(00)00241-9
   PubMed Web of Science ®Google Scholar
• Blanco C, Petkova E, Ibáñez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14(1):9–15. doi: 10.3109/10401230209147393
   PubMedGoogle Scholar
• Kim SW, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(6):501–507. doi: 10.4088/JCP.v63n0606
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. 2003;18(4):243–249. doi: 10.1097/01.yic.0000073881.93678.21
   PubMed Web of Science ®Google Scholar
• Saiz-Ruiz J, Blanco C, Ibáñez A, et al. Sertraline treatment of pathological gambling. J Clin Psychiatry. 2005;66(1):28–33. doi: 10.4088/JCP.v66n0104
   PubMed Web of Science ®Google Scholar
• Myrseth H, Molde H, Støylen IJ, et al. A pilot study of CBT versus escitalopram combined with CBT in the treatment of pathological gamblers. Int Gambl Stud. 2011;11(1):121–141. doi: 10.1080/14459795.2011.559647
   Web of Science ®Google Scholar
• Black DW, Shaw M, Forbush KT, et al. An open-label trial of escitalopram in the treatment of pathological gambling. Clin Neuropharmacol. 2007;30(4):206–212. doi: 10.1097/wnf.0b013e31803d357f
   PubMed Web of Science ®Google Scholar
• Zimmerman BR, Posternak MA, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(1):44–48. doi: 10.4088/JCP.v63n0109
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Odlaug BL. N-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62(6):652–657. doi: 10.1016/j.biopsych.2006.11.021
   PubMed Web of Science ®Google Scholar
• Black DW, McNeilly DP, Burke WJ, et al. An open-label trial of acamprosate in the treatment of pathological gambling. Ann Clin Psychiatry. 2011;23(4):250–256.
   PubMed Web of Science ®Google Scholar
• Grant JE, Chamberlain SR, Odlaug BL, et al. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology. 2010;212(4):603–612. doi: 10.1007/s00213-010-1994-5
   PubMed Web of Science ®Google Scholar
• Berlin HA, Braun A, Simeon D, et al. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry. 2013;14(2):121–128. doi: 10.3109/15622975.2011.560964
   PubMed Web of Science ®Google Scholar
• de B AM, de AP MG, Bronstein G, et al. Topiramate combined with cognitive restructuring for the treatment of gambling disorder: a two-center, randomized, double-blind clinical trial. J Gambl Stud. 2017;33(1):249–263. doi: 10.1007/s10899-016-9620-z
   PubMed Web of Science ®Google Scholar
• Black DW, Shaw MC, Allen J. Extended release carbamazepine in the treatment of pathological gambling: an open-label study. Prog Neuro Psychopharmacol Biol Psychiatry. 2008;32(5):1191–1194. doi: 10.1016/j.pnpbp.2008.02.013
   PubMed Web of Science ®Google Scholar
• Zack M, Poulos C. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol. 2009;23(6):660–671. doi: 10.1177/0269881108091072
   PubMed Web of Science ®Google Scholar
• Smart K, Desmond RC, Poulos CX, et al. Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers. Neuropharmacology. 2013;73:66–74. doi: 10.1016/j.neuropharm.2013.05.015
   PubMed Web of Science ®Google Scholar
• Pallanti S, Rossi NB, Sood E, et al. Nefazodone treatment of pathological gambling. J Clin Psychiatry. 2002;63(11):1034–1039. doi: 10.4088/JCP.v63n1114
   PubMed Web of Science ®Google Scholar
• Fong T, Kalechstein A, Bernhard B, et al. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89(3):298–303. doi: 10.1016/j.pbb.2007.12.025
   PubMed Web of Science ®Google Scholar
• McElroy SL, Nelson EB, Welge JA, et al. Olanzapine in the treatment of pathological gambling. J Clin Psychiatry. 2008;69(3):433–440. doi: 10.4088/JCP.v69n0314
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Chamberlain SR, et al. A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol. 2013;23(11):1587–1596. doi: 10.1016/j.euroneuro.2013.07.008
   PubMed Web of Science ®Google Scholar
• Kayser AS, Vega T, Weinstein D, et al. Right inferior frontal cortex activity correlates with tolcapone responsivity in problem and pathological gamblers. NeuroImage Clin. 2017;13:339–348. doi: 10.1016/j.nicl.2016.12.022
   PubMed Web of Science ®Google Scholar
• Black DW. An open-label trial of bupropion in the treatment of pathologic gambling. J Clin Psychopharmacol. 2004;24(1):108–110. doi: 10.1097/01.jcp.0000114844.58996.4a
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion in the treatment of SSRI nonresponder pathologic gamblers: pilot study and review of the literature. Therapy. 2005;2(5):753–757. doi: 10.2217/14750708.2.5.753
   Google Scholar
• Black DW, Arndt S, Coryell WH, et al. Bupropion in the treatment of pathological gambling. J Clin Psychopharmacol. 2007;27(2):143–150. doi: 10.1097/01.jcp.0000264985.25109.25
   PubMed Web of Science ®Google Scholar
• Bae S, Hong JS, Kim SM, et al. Bupropion shows different effects on brain functional connectivity in patients with internet-based gambling disorder and internet gaming disorder. Front Psychiatry. 2018;9. doi: 10.3389/fpsyt.2018.00130
   Web of Science ®Google Scholar
• Kraus SW, Etuk R, Potenza MN. Current pharmacotherapy for gambling disorder: a systematic review. Expert Opin Pharmacother. 2020;21(3):287–296. doi: 10.1080/14656566.2019.1702969
   PubMed Web of Science ®Google Scholar
• Grant JE, Chamberlain SR. Gambling and substance use: comorbidity and treatment implications. Prog Neuro Psychopharmacol Biol Psychiatry. 2020;99:109852. doi: 10.1016/j.pnpbp.2019.109852
   PubMed Web of Science ®Google Scholar
• Abbott MW. Professionally delivered interventions for gambling disorder. Curr Opin Psychiatry. 2019;32(4):313–319. doi: 10.1097/YCO.0000000000000516
   PubMed Web of Science ®Google Scholar
• Di Nicola M, De Crescenzo F, D’Alò GL, et al. Pharmacological and psychosocial treatment of adults with gambling disorder: a meta-review. J Addict Med. 2020;14(4):e15–e23. doi: 10.1097/ADM.0000000000000574
   PubMed Web of Science ®Google Scholar
• Toneatto T, Brands B, Selby PA. Randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18:219–225. doi: 10.1080/10550490902787007
   PubMed Web of Science ®Google Scholar
• Mouaffak F, Leite C, Hamzaoui S, et al. Naltrexone in the treatment of broadly defined behavioral addictions: a review and meta-analysis of randomized controlled trials. Eur Addict Res. 2017;23(4):204–210. doi: 10.1159/000480539
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Double-Blind OBA. Placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry. 2009;65:600–606. doi: 10.1016/j.biopsych.2008.11.022
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Schreiber LRN, et al. The opiate antagonist, naltrexone, in the treatment of trichotillomania. J Clin Psychopharmacol. 2014;34(1):134–138. doi: 10.1097/JCP.0000000000000037
   PubMed Web of Science ®Google Scholar
• Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83(9):826–833. doi: 10.1212/WNL.0000000000000729
   PubMed Web of Science ®Google Scholar
• Bartley CA, Bloch MH. Meta-analysis: pharmacological treatment of pathological gambling. Expert Rev Neurother. 2013;13(8):887–894. doi: 10.1586/14737175.2013.814938
   PubMed Web of Science ®Google Scholar
• Dowling N, Merkouris S, Lubman D, et al. Pharmacological interventions for the treatment of disordered and problem gambling. Cochrane Database Syst Rev. 2022;2022. doi: 10.1002/14651858.CD008936.pub2
   Google Scholar
• Aboujaoude E, Salame WO. Naltrexone: a pan-addiction treatment? CNS Drugs. 2016;30:719–733. doi: 10.1007/s40263-016-0373-0
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Hollander E, et al. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology. 2008;200(4):521–527. doi: 10.1007/s00213-008-1235-3
   PubMed Web of Science ®Google Scholar
• Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21(4):203–209. doi: 10.1097/00004850-200607000-00002
   PubMed Web of Science ®Google Scholar
• Pettorruso M, De Risio L, Martinotti G, et al. Targeting the glutamatergic system to treat pathological gambling: Current evidence and future perspectives. Biomed Res Int. 2014;2014:1–11. doi: 10.1155/2014/109786
   Web of Science ®Google Scholar
• Asevedo E, Mendes AC, Berk M, et al. Systematic review of N-acetylcysteine in the treatment of addictions. Rev Bras Psiquiatr. 2014;36(2):168–175. doi: 10.1590/1516-4446-2013-1244
   PubMed Web of Science ®Google Scholar
• Deepmala SJ, Kumar N, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. 2015;55:294–321. doi: 10.1016/j.neubiorev.2015.04.015
   PubMed Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Chamberlain SR, et al. A randomized, placebo-controlled trial of N -Acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014;75(1):39–45. doi: 10.4088/JCP.13m08411
   PubMed Web of Science ®Google Scholar
• Sani G, Serra G, Kotzalidis GD, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias. CNS Drugs. 2012;26(8):663–690. doi: 10.2165/11634390-000000000-00000
   PubMed Web of Science ®Google Scholar
• Olive MF, Cleva RM, Kalivas PW, et al. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav. 2012;100(4):801–810. doi: 10.1016/j.pbb.2011.04.015
   PubMed Web of Science ®Google Scholar
• Nourredine M, Jurek L, Angerville B, et al. Use of topiramate in the spectrum of addictive and eating disorders: a systematic review comparing treatment schemes, efficacy, and safety features. CNS Drugs. 2021;35(2):177–213. doi: 10.1007/s40263-020-00780-y
   PubMed Web of Science ®Google Scholar
• Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162(1):137–145. doi: 10.1176/appi.ajp.162.1.137
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling. J Clin Psychiatry. 2002;63(7):559–564. doi: 10.4088/JCP.v63n0704
   PubMed Web of Science ®Google Scholar
• Tremblay A-M, Desmond RC, Poulos CX, et al. Haloperidol modifies instrumental aspects of slot machine gambling in pathological gamblers and healthy controls. Addict Biol. 2011;16(3):467–484. doi: 10.1111/j.1369-1600.2010.00208.x
   PubMed Web of Science ®Google Scholar
• Zack M, Poulos CX. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology. 2007;32(8):1678–1686. doi: 10.1038/sj.npp.1301295
   PubMed Web of Science ®Google Scholar
• Padala PR, Madaan V, Sanar SP. Bupropion therapy for pathological gambling. Ann Pharmacother. 2007;41(3):529–529. doi: 10.1345/aph.1H311
   PubMed Web of Science ®Google Scholar
• Dannon PN, Rosenberg O, Schoenfeld N, et al. Acamprosate and baclofen were not effective in the treatment of pathological gambling: preliminary blind rater comparison study. Front Psychiatry. 2011;2. doi: 10.3389/fpsyt.2011.00033
   PubMedGoogle Scholar
• Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling. Clin Neuropharmacol. 2005;28(1):6–10. doi: 10.1097/01.wnf.0000152623.46474.07
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling. J Clin Psychopharmacol. 2005;25(6):593–596. doi: 10.1097/01.jcp.0000186867.90289.ed
   PubMed Web of Science ®Google Scholar
• Rosenberg O, Dinur LK, Dannon PN. Four-year follow-up study of pharmacological treatment in pathological gamblers. Clin Neuropharmacol. 2013;36(2):42–45. doi: 10.1097/WNF.0b013e31828740ea
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Musin E, et al. 12-month follow-up study of drug treatment in pathological gamblers. J Clin Psychopharmacol. 2007;27(6):620–624. doi: 10.1097/jcp.0b013e31815a4400
   PubMed Web of Science ®Google Scholar
• Di Nicola M, De Risio L, Pettorruso M, et al. Bipolar disorder and gambling disorder comorbidity: Current evidence and implications for pharmacological treatment. J Affect Disord. 2014;167:285–298. doi: 10.1016/j.jad.2014.06.023
   PubMed Web of Science ®Google Scholar
• Moore LH, Grubbs JB. Gambling disorder and comorbid PTSD: a systematic review of empirical research. Addict Behav. 2021;114:106713. doi: 10.1016/j.addbeh.2020.106713
   PubMed Web of Science ®Google Scholar
• Cowlishaw S, Merkouris S, Chapman A, et al. Pathological and problem gambling in substance use treatment: a systematic review and meta-analysis. J Subst Abuse Treat. 2014;46(2):98–105. doi: 10.1016/j.jsat.2013.08.019
   PubMed Web of Science ®Google Scholar
• Grant JE, Potenza MN, Kraus SW, et al. Naltrexone and disulfiram treatment response in veterans with alcohol dependence and co-occurring problem-gambling features. J Clin Psychiatry. 2017;78(9):e1299–e1306. doi: 10.4088/JCP.16m11220
   PubMed Web of Science ®Google Scholar
• Hollander E, Buchsbaum MS, Haznedar MM, et al. FDG-PET study in pathological gamblers: 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism. Neuropsychobiology. 2008;58(1):37–47. doi: 10.1159/000154478
   PubMedGoogle Scholar
• Mannu P, Minnai GG. Quetiapine in the treatment of pathological gambling associated with bipolar disorder. Riv Psichiatr. 2005;40:360–364.
   Google Scholar
• Lowengrub K, Iancu I, Aizer A, et al. Pharmacotherapy of pathological gambling: review of new treatment modalities. Expert Rev Neurother. 2006;6(12):1845–1851. doi: 10.1586/14737175.6.12.1845
   PubMedGoogle Scholar
• Bullock SA, Potenza MN. Pathological gambling: neuropsychopharmacology and treatment. Curr Psychopharmacol. 2012;1(1):67–85. doi: 10.2174/2211557911201010067
   Google Scholar
• Pfund RA, Ginley MK, Kim HS, et al. Cognitive-behavioral treatment for gambling harm: umbrella review and meta-analysis. Clin Psychol Rev. 2023;105:102336. doi: 10.1016/j.cpr.2023.102336
   PubMed Web of Science ®Google Scholar
• Pfund RA, King SA, Forman DP, et al. Effects of cognitive behavioral techniques for gambling on recovery defined by gambling, psychological functioning, and quality of life: a systematic review and meta-analysis. Psychol Addict Behav. 2023;37(7):936–945. doi: 10.1037/adb0000910
   PubMed Web of Science ®Google Scholar
• Pfund RA, Forman DP, Whalen SK, et al. Effect of cognitive‐behavioral techniques for problem gambling and gambling disorder: a systematic review and meta‐analysis. Addiction. 2023;118(9):1661–1674. doi: 10.1111/add.16221
   PubMed Web of Science ®Google Scholar
• Petry NM. Pathological gambling: etiology, comorbidity, and treatment. 1st ed. Washington, DC: American Psychological Association; 2004.
   Google Scholar
• Ladouceur R, Lachance S. Overcoming pathological gambling (treatments that work). 1st ed. Oxford University Press; 2006.
   Google Scholar
• Bodor D, Ricijaš N, Filipčić I. Treatment of gambling disorder: review of evidence-based aspects for best practice. Curr Opin Psychiatry. 2021;34(5):508–513. doi: 10.1097/YCO.0000000000000728
   PubMed Web of Science ®Google Scholar
• Mestre-Bach G, Potenza MN. Neuroimaging correlates of internet gaming disorder: can we achieve the promise of translating understanding of brain functioning into clinical advances? Can J Addict. 2023;14(3):7–17. doi: 10.1097/CXA.0000000000000178
   PubMed Web of Science ®Google Scholar
• Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry Online. 2010;167(7):748–751. doi: 10.1176/appi.ajp.2010.09091379
   PubMed Web of Science ®Google Scholar
• Hamilton KR, Littlefield AK, Anastasio NC, et al. Rapid-response impulsivity: definitions, measurement issues, and clinical implications personal disord theory. Res Treat. 2015;6(2):168–181. doi: 10.1037/per0000100
   Google Scholar
• Hamilton KR, Mitchell MR, Wing VC, et al. Choice impulsivity: definitions, measurement issues, and clinical implications. Personal Disord. 2015;6(2):182–198. doi: 10.1037/per0000099
   PubMedGoogle Scholar
• Blanco C, Potenza MN, Kim SW, et al. A pilot study of impulsivity and compulsivity in pathological gambling. Psychiatry Res. 2009;167(1–2):161–168. doi: 10.1016/j.psychres.2008.04.023
   PubMed Web of Science ®Google Scholar
• Grant J, Odlaug B, Chamberlain S, et al. Open-label memantine treatment of pathological gambling reduces gambling severity and cognitive inflexibility. Psychopharmacol. 2010;212(4):603–612. doi: 10.1007/s00213-010-1994-5
   PubMed Web of Science ®Google Scholar
• Yip SW, Worhunsky PD, Xu J, et al. Gray-matter relationships to diagnostic and transdiagnostic features of drug and behavioral addictions. Addict Biol. 2018;23(1):394–402. doi: 10.1111/adb.12492
   PubMed Web of Science ®Google Scholar
• Dowling NA, Merkouris SS, Lorains FK. Interventions for comorbid problem gambling and psychiatric disorders: advancing a developing field of research. Addict Behav. 2016;58:21–30. doi: 10.1016/j.addbeh.2016.02.012
   PubMed Web of Science ®Google Scholar
• Beckenstrom AC, Coloma PM, Dawson GR, et al. Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation. Neurosci Biobehav Rev. 2023;147:105107. doi: 10.1016/j.neubiorev.2023.105107
   PubMed Web of Science ®Google Scholar
• Blaszczynski A, Nower L. A pathways model of problem and pathological gambling. Addiction. 2002;97(5):487–499. doi: 10.1046/j.1360-0443.2002.00015.x
   PubMed Web of Science ®Google Scholar
• Bonnaire C, Devos G, Barrault S, et al. An empirical investigation of the pathways model of problem gambling through the conjoint use of self-reports and behavioural tasks. J Behav Addict. 2022;11(3):858–873. doi: 10.1556/2006.2022.00055
   PubMed Web of Science ®Google Scholar
• Nower L, Blaszczynski A. Development and validation of the gambling pathways questionnaire (GPQ). Psychol Addict Behav. 2017;31(1):95–109. doi: 10.1037/adb0000234
   PubMed Web of Science ®Google Scholar
• Marchica L, Derevensky JL. Examining personalized feedback interventions for gambling disorders: a systematic review. J Behav Addict. 2016;5(1):1–10. doi: 10.1556/2006.5.2016.006
   PubMed Web of Science ®Google Scholar
• Wu L, Xu J, Song K, et al. Emotional bias modification weakens game-related compulsivity and reshapes frontostriatal pathways. Brain. 2022;145(12):4210–4221. doi: 10.1093/brain/awac267
   PubMed Web of Science ®Google Scholar
• Lu WL, Potenza MN, Zhou N, et al. A role for the right dorsolateral prefrontal cortex in enhancing regulation of both craving and negative emotions in internet gaming disorder: a randomized trial. Eur Neuropsychopharmacol. 2020;36:29–37. doi: 10.1016/j.euroneuro.2020.04.003
   PubMed Web of Science ®Google Scholar
• Carroll KM. Treatment integrity and dissemination: rethinking fidelity via the stage model. Clin Psychol Sci Pract. 2013;20(1):99–106. doi: 10.1111/cpsp.12025
   Web of Science ®Google Scholar
• McCurdy LY, Loya JM, Hart-Derrick VR, et al. Smartphone apps for problem gambling: a review of content and quality. Curr Addict Reports. 2023;10(2):178–186. doi: 10.1007/s40429-023-00479-2
   PubMedGoogle Scholar
• Bijker R, Booth N, Merkouris SS, et al. Global prevalence of help‐seeking for problem gambling: a systematic review and meta‐analysis. Addiction. 2022;117(12):2972–2985. doi: 10.1111/add.15952
   PubMed Web of Science ®Google Scholar
• Pilver CE, Potenza MN. Increased incidence of cardiovascular conditions among older adults with pathological gambling features in a prospective study. J Addict Med. 2013;7(6):387–393. doi: 10.1097/ADM.0b013e31829e9b36
   PubMed Web of Science ®Google Scholar
• Desai RA, Desai MM, Potenza MN. Gambling, health and age: data from the national epidemiologic survey on alcohol and related conditions. Psychol Addict Behav. 2007;21(4):431–440. doi: 10.1037/0893-164X.21.4.431
   PubMed Web of Science ®Google Scholar
• Barry DT, Pilver CE, Hoff RA, et al. Pain interference, gambling problem severity, and psychiatric disorders among a nationally representative sample of adults. J Behav Addict. 2013;2(3):138–144. doi: 10.1556/JBA.2.2013.010
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse Control Disorders in Parkinson Disease. Arch Neurol. 2010;67(5):67. doi: 10.1001/archneurol.2010.65
   Google Scholar
• Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case–control study. Ann Neurol. 2011;69(6):986–996. doi: 10.1002/ana.22356
   PubMed Web of Science ®Google Scholar
• Wolfschlag M, Håkansson A. Drug-induced gambling disorder: epidemiology, neurobiology, and management. Pharmaceut Med. 2023;37(1):37–52. doi: 10.1007/s40290-022-00453-9
   PubMed Web of Science ®Google Scholar
• Pettorruso M, Di Carlo F, Romeo VM, et al. The pharmacological management of gambling disorder: if, when, and how. Expert Opin Pharmacother. 2023;24(4):419–423. doi: 10.1080/14656566.2023.2172329
   PubMed Web of Science ®Google Scholar
• Martinotti G, Dell’osso B, Di Lorenzo G, et al. Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression. Bipolar Disord. 2023;25(3):233–244. doi: 10.1111/bdi.13296
   PubMed Web of Science ®Google Scholar
• Pettorruso M, Martinotti G, Montemitro C, et al. Multiple sessions of high-frequency repetitive transcranial magnetic stimulation as a potential treatment for gambling addiction: a 3-month, feasibility study. Eur Addict Res. 2020;26(1):52–56. doi: 10.1159/000504169
   PubMed Web of Science ®Google Scholar
• Martinotti G, Pettorruso M, Montemitro C, et al. Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: a randomized, double-blind, sham-controlled trial. Prog Neuro Psychopharmacol Biol Psychiatry. 2022;116:110513. doi: 10.1016/j.pnpbp.2022.110513
   PubMed Web of Science ®Google Scholar
• Science has a gambling problem. Nature. 2018;553(7689):379–379. doi: 10.1038/d41586-018-01051-z
   Web of Science ®Google Scholar
• https://www.ncpgambling.org/advocacy/grit-act/
   Google Scholar